SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market anticipates the government shutdown potentially ending, with Congress working towards a deal, although some worry that positive news is already priced in. The community is weighing the potential for a "sell the news" event against optimism for continued gains, especially with potential delays in key economic data releases. Broader market sentiment remains cautiously optimistic, though the impact of the shutdown and potential rate cuts are also being considered.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending amid anticipation for upcoming data presentations at the Skin Disease Symposium in NYC, with discussion focused on the potential of their SLK drug and speculation around institutional investment. Community members are highlighting the possibility of a short squeeze and a return to previous highs, while also noting an upcoming FDA meeting as a key catalyst. The discussion also includes speculation about a potential buyout, given the company's promising pipeline and recent financial activity.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending amidst discussions about its relationship with the newly launched Janction (JCT) token, with some community members debating whether JCT's creation benefits or detracts from JASMY. Some believe JCT expands the Jasmy ecosystem and drives demand, while others fear it signals a shift away from JASMY. Despite the divided opinions, the high volume and trending status indicate significant interest in the project's future.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders react to the House passing a bill to end the government shutdown and anticipate Trump's signature. While some community members are optimistic about a potential rally, others believe the news is already priced in and are watching for a "sell the news" event or a sector rotation. There is also a lot of talk about a possible AI bubble and the potential impact of delayed economic data.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending as the community anticipates upcoming earnings and considers the potential impact of an expiring IPO lockup period. Discussions revolve around whether the stock is currently oversold, presenting a buying opportunity, or if insider selling will create further downward pressure. Some traders highlight the potential of stablecoins while others express concerns about competition and regulatory hurdles.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors digest recent news, including a new equity distribution agreement and analyst target adjustments. Community discussions revolve around the company's growth potential in the AI data center space versus concerns about dilution and cash burn. Some traders are closely watching technical levels and market sentiment for potential entry points.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending due to a potential short squeeze, fueled by an upcoming warrant distribution and the CEO's recent stock purchase, signaling strong confidence. The community is actively discussing the possibility of a significant squeeze, drawing comparisons to other high-profile situations and highlighting the warrant issuance as a key catalyst for short covering. Amidst this, some traders have pointed to potentially dilutive effects to the stock price.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending as investors anticipate earnings results, with the community focusing on potential growth catalysts like streaming profitability and theme park performance. Bullish sentiment is fueled by technical indicators suggesting a potential breakout, while some remain cautious due to past performance and broader market conditions. Discussions also include Disney's content strategy and its relationship with streaming platforms like YouTube TV.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to activist investor Shah Capital pushing for the company's sale, citing management's "profound lack of competence" and expressing frustration over Novavax's minuscule COVID vaccine market share. The community is echoing Shah's concerns, criticizing CEO John Jacobs' leadership and advocating for a sale to a larger pharmaceutical company. Discussions center on whether a sale is the best path forward, given the company's struggles in the competitive vaccine market.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is trending as discussions revolve around its recent Q3 earnings and acquisition of Ask Sage, which is expected to bolster its AI capabilities for defense and national security. Community members are drawing comparisons to Palantir ($PLTR), speculating on potential government contracts, particularly with the government possibly re-opening soon. Positive sentiment is building around BBAI's future growth and potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Clear Street cut its price target to $7 from $93, saying KRRO-110 failed to reach protective protein levels in its Phase 1/2 study for Alpha-1 Antitrypsin Deficiency.</li><li>Korro said differences between healthy volunteers and patients guided its pivot to a GalNAc delivery approach, with a new AATD candidate expected in early 2026.</li><li>Retail traders on StockTwits pointed to the company’s cash position and second pipeline program.</li></ul>Korro Bio shares crashed over 75% after-hours on Wednesday after analysts downgraded the stock and the company said it would cut about 34% of its workforce following disappointing results from its lead drug for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic condition in which the liver does not make enough of a protein needed to protect the lungs.<h2 class="st-heading-2">Analyst Downgrades&nbsp;</h2>Clear Street downgraded Korro Bio to ‘Hold’ from ‘Buy’ and cut its price target to $7 from $93. The analyst said KRRO-110 failed to&nbsp;achieve protective levels of the corrected protein in its Phase 1/2 trial for Alpha-1 Antitrypsin Deficiency, leading to the discontinuation of development. The analyst also said that with the step back in timeline and the move away from its lipid nanoparticles (LNP) delivery approach, Korro’s positioning in the disorder is “compromised.”Cantor Fitzgerald also downgraded the stock, moving its rating to ‘Neutral’ from ‘Overweight’.<h2 class="st-heading-2">Lead Drug Falls Short In Early Trial</h2>Korro said KRRO-110 did produce functional protein in patients with Alpha-1 Antitrypsin Deficiency, but did not reach the levels it predicted from earlier preclinical work. The company said differences between healthy volunteers and AATD patients contributed to its pivot toward a new delivery approach called GalNAc. A new AATD development candidate using this approach is expected in the first half of 2026.<h2 class="st-heading-2">Pipeline Pivot</h2>Korro also nominated KRRO-121, a GalNAc-conjugated RNA-editing therapy designed for patients with hyperammonemia. The company plans to move the program into clinical testing in the second half of 2026.<h2 class="st-heading-2">Workforce Reduction&nbsp;</h2>Korro said it will reduce its workforce by nearly 34%, with the cuts affecting all levels of the organization. The company said the restructuring is expected to extend its cash runway into the second half of 2027, giving it sufficient capital to deliver clinical data from KRRO-121, advance at least one additional program, and conduct partnership discussions to broaden pipeline development.Korro also said it expects to incur about $2.4 million in one-time restructuring charges, including employee severance, benefits, and related termination costs, most of which it expects to recognize during the fourth quarter of 2025.<h2 class="st-heading-2">Executive Exit</h2>Korro said Chief Medical Officer Kemi Olugemo resigned, effective Wednesday. The company ended the third quarter with $102.5 million in cash, cash equivalents, and marketable securities. Collaboration revenue for the period was $1.1 million, and net loss totaled $18.1 million.<h2 class="st-heading-2">Stocktwits Users Flag Cash Position&nbsp;</h2>On Stocktwits, retail sentiment for Korro was ‘extremely bullish’ amid ‘extremely high’ message volume, placing it among the top five trending equities on the platform.&nbsp;<figure class="image"><img style="aspect-ratio:970/145;" src="https://news.stocktwits-cdn.com/krro_ss_jpg_f7790cba96.webp" alt="krro ss.jpg" width="970" height="145"><figcaption>KRRO sentiment and message volume as of November 12 | Source: Stocktwits</figcaption></figure>One user suggested the stock could recover toward $10 in the morning, noting the company has ample cash and another program in development that could resonate with investors.<stembedurl>https://stocktwits.com/murphylaw/message/635974154</stembedurl>Another user said the pullback was a buying opportunity, arguing that the company has significant cash on hand and a second product in the pipeline.<stembedurl>https://stocktwits.com/murphylaw/message/635976345</stembedurl><a href="https://stocktwits.com/symbol/KRRO">Korro’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Korro’s stock (KRRO) has declined 17% so far in 2025. (Photo credit: Getty Images)

Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setup

Clear Street cut its price target to $7 from $93, saying KRRO-110 failed to reach protective protein levels in its Phase 1/2 study for Alpha-1 Antitrypsin Deficiency.

Equity

Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates

Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of +26.44% and -27.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

180 Life Sciences (ATNF) 180 Life Sciences surged more than 500% on Wednesday becoming the top gainer across U.S. exchanges, boosting retail sentiment.The <a href="https://stocktwits.com/news-articles/markets/equity/atnf-stock-surges-on-online-gaming-pivot/cJcz40JRIG">sharp rally</a> followed the company’s announcement of its strategic pivot into online gaming, or iGaming, a move that seems to have sent retail investors into a frenzy.Retail sentiment on Stocktwits has skyrocketed to ‘extremely bullish’ (97/100) from ‘neutral’ a day ago.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_223155_cd82ae123f.png" alt="Screenshot 2024-10-16 223155.png">NuScale Power Corp. (SMR)NuScale Power shares surged 33% on Wednesday, buoyed by <a href="https://stocktwits.com/news-articles/markets/equity/amazon-signs-agreements-to-support-nuclear-energy-development/cJcza0dRIc">Amazon's decision</a> to invest in nuclear energy to power its data centers and other facilities at its Washington state headquarters.NuScale specializes in small modular reactors (SMRs), the same cutting-edge technology Amazon is considering to meet its growing energy demands. The stock soared to an all-time high of $18.01, marking a remarkable 473% year-to-date increase.Retail sentiment on Stocktwits has dramatically shifted, moving from 'bearish' to 'extremely bullish' (97/100) within a day.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_225310_41cad3a0dc.png" alt="Screenshot 2024-10-16 225310.png">Korro Bio (KRRO)Korro Bio's shares skyrocketed 111% on Wednesday following Wave Life Sciences’ <a href="https://stocktwits.com/news-articles/markets/equity/wave-life-sciences-stock-surges-on-rna-editing-breakthrough/cJczOOPRI5">announcement</a> of early validation for its latest RNA editing technology, a promising breakthrough in the field of genetic medicine.Korro Bio is heavily investing in RNA editing therapies, specifically targeting Alpha-1 Antitrypsin Deficiency (AATD). The company plans to seek regulatory approval by the end of the year to begin clinical trials for its RNA editing treatments.Retail sentiment around the company on Stocktwits has been initiated at ‘extremely bullish’ (97/100).<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_231152_5247ea7ca2.png" alt="Screenshot 2024-10-16 231152.png">For updates and corrections email newsroom@stocktwits.com.Read more:<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-falls-after-robotaxi-event-underwhelms/cJcVcLcR4T">&nbsp;</a><a href="https://stocktwits.com/news-articles/markets/equity/abbott-labs-stock-dips-pre-market-on-narrowed-profit-outlook-retail-turns-bearish/cJcz2u7R4D">Abbott Labs Stock Dips Pre-Market On Narrowed Profit Outlook: Retail Turns Bearish</a>

Rising stock prices of 180 Life Sciences, Korro Bio, and NuScale Power fuel bullish retail sentiment on Stocktwits

180 Life Sciences, Korro Bio, NuScale Power: Retail Investors Turn Most Bullish On These Stocks

Small-cap stocks like Korro Bio and NuScale Power are benefiting from the momentum generated by larger stocks.

Korro Bio Board Changes and Strategic Advisor Agreement

An announcement from Korro Bio (KRRO) is now available. David L. Lucchino resigned from our Board of Directors on August 26, 2024, but will stay co...

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer...

Piper Sandler Reiterates Overweight Rating for Korro Bio (NASDAQ:KRRO)

Piper Sandler restated their overweight rating on shares of Korro Bio (NASDAQ:KRRO - Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Piper Sandler currently has a...

We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Korro Bio (NASDAQ:KRRO) Price Target Increased to $115.00 by Analysts at HC Wainwright

Korro Bio (NASDAQ:KRRO  Free Report) had its price target lifted by HC Wainwright from $100.00 to $115.00 in a research note published on Thursday, Marketbeat Ratings reports. The firm...

Korro Bio (NASDAQ:KRRO) Rating Reiterated by Piper Sandler

Korro Bio (NASDAQ:KRRO  Get Free Report)s stock had its overweight rating restated by equities research analysts at Piper Sandler in a report issued on Wednesday, Benzinga...

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$2.54	--	--	N/A
Q3 '25	-$2.59	-$1.92	25.98%	BEAT
Q2 '25	-$2.57	-$2.74	-6.80%	MISSED
Q1 '25	-$2.58	-$2.49	3.56%	BEAT
Q4 '24	-$2.50	-$2.24	10.40%	BEAT

KRRO
Korro Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest KRRO News

KRROKorro Bio Inc.